XML 28 R18.htm IDEA: XBRL DOCUMENT
v3.25.1

GOODWILL AND INTANGIBLE ASSETS | 3 Months Ended
--- | ---
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND INTANGIBLE ASSETS | GOODWILL AND INTANGIBLE ASSETS Goodwill As of March 31, 2025, the Company has assigned its goodwill in three reporting units, Generics and Other, Brands, and Rare Disease reporting units. As a result of the 2013 merger with BioSante Pharmaceuticals, Inc., the Company recorded goodwill of $1.8 million. As a result of the acquisition of WellSpring Pharma Services Inc. in 2018, the Company recorded goodwill of $1.7 million. From the acquisition of Noviti um in 2021, the Company recorded goodwill of $24.6 million. The goodwill from the transactions with BioSante Pharmaceuticals, Inc., WellSpring Pharma Services Inc., and Novitium is recorded in the Generics and Other reporting unit. As a result of the acquisition of Alimera, on September 16, 2024, the Company recorded goodwill of $32.4 million in the Rare Disease reporting unit. Refer to Note 3 “Business Combination” to the notes to the condensed consolidated financial statements (unaudited) for further information related to the acquisition. There have been no events or changes in circumstances that would have reduced the fair value of the reporting units below their carrying value during the three months ended March 31, 2025, and 2024, respectively, and as a result no impairment charges have been recognized. Intangible Assets The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows:
| March 31, 2025 |  | December 31, 2024 | Remaining Weighted Average Amortization Period(1)
(in thousands) | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount |  | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount
Definite-Lived Intangible Assets: |  |  |  |  |  |  |  |
Acquired ANDAs intangible assets | $ | 210,620 |  | $ | (130,895) |  | $ | 79,725 |  |  | $ | 210,497 |  | $ | (124,874) |  | $ | 85,623 |  | 4.2 years
NDAs and product rights | 658,521 |  | (229,980) |  | 428,541 |  |  | 641,271 |  | (216,420) |  | 424,851 |  | 10.8 years
Marketing and distribution rights | 17,157 |  | (15,474) |  | 1,683 |  |  | 17,157 |  | (15,233) |  | 1,924 |  | 1.8 years
Customer relationships | 24,900 |  | (12,154) |  | 12,746 |  |  | 24,900 |  | (11,264) |  | 13,636 |  | 3.6 years
Total Definite-Lived Intangible Assets | 911,198 |  | (388,503) |  | 522,695 |  |  | 893,825 |  | (367,791) |  | 526,034 |  | 9.6 years
Indefinite-Lived Intangible Assets: |  |  |  |  |  |  |  |
In process research and development | 15,800 |  | — |  | 15,800 |  |  | 15,800 |  | — |  | 15,800 |  | Indefinite
Total Intangible Assets, net | $ | 926,998 |  | $ | (388,503) |  | $ | 538,495 |  |  | $ | 909,625 |  | $ | (367,791) |  | $ | 541,834 |  |
(1)Weighted average amortization period as of March 31, 2025. Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (“ANDAs”), New Drug Applications (“NDAs”) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that these assets might be impaired. During the year ended December 31, 2024, the Company acquired Alimera, and as a result, acquired two intangible assets for YUTIQ and ILUVIEN, in the amount of $170.0 million and $230.0 million, respectively, which will be amortized over twelve years. Pursuant to a Royalty Purchase Agreement dated as of December 17, 2020, EyePoint Pharmaceuticals US, Inc. (f/k/a pSivida US, Inc. or “EyePoint”) sold its right to receive royalty payments on future sales of ILUVIEN to SWK Funding LLC (“SWK”) under an existing collaboration agreement entered into in July 2017 between EyePoint and the Company (the “RPA Transaction”). In connection with the RPA Transaction, the Company agreed to pay such royalty payments directly to SWK. On June 19, 2024, Alimera entered into a letter agreement with SWK, pursuant to which the parties agreed to a lower fixed royalty payment of 3.125% (the “Alternative Royalty”) on combined sales of ILUVIEN and YUTIQ. The letter agreement included a buy-out of the Alternative Royalty at Alimera’s option at any time during the period within six (6) months after a change of control of Alimera, after which SWK would have no further right to receive any payments under the letter agreement or the RPA (the “Buy-Out Option”). On March 17, 2025, the Company exercised the Buy-Out Option and paid SWK $17.3 million with cash on hand, and as such, no further royalty is due to SWK on net revenues beginning January 1, 2025, forward. The purchase of the Buy-Out Option was recorded as a definite-lived intangible asset, which will be amortized over approximately twelve years, consistent with the useful lives of YUTIQ and ILUVIEN. The SWK definite-lived intangible asset is included in the "NDAs and product rights" in the table above. Amortization expense for definite-lived intangibles was $20.7 million and $13.0 million for the three months ended March 31, 2025 and 2024, respectively. Indefinite-lived intangible assets other than goodwill include primarily In-Process Research & Development (“IPR&D”) projects. IPR&D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&D project is completed (generally upon receipt of regulatory approval), then the IPR&D will be accounted for as a definite-lived intangible asset. Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets annually as of October 31, 2024, as well as with definite-lived intangibles when events or circumstances indicate that the carrying value of the assets may not be recoverable. The Company performed qualitative assessments to determine whether it was more likely than not that the assets were impaired in order to determine the necessity of performing a quantitative impairment test, under which management would calculate the asset’s fair value. When performing the qualitative assessments, the Company evaluated events and circumstances that would affect the significant inputs used to determine the fair value of the assets. No impairment charges were recognized in the three months ended March 31, 2025 and 2024, respectively. Expected future amortization expense for definite-lived intangible assets is as follows:
(in thousands) |
2025 (remainder of the year) | $ | 60,306 |
2026 | 67,532 |
2027 | 58,565 |
2028 | 52,574 |
2029 | 46,348 |
2030 and thereafter | 237,370 |
Total | $ | 522,695 |
Expected amortization expense is an estimate. Actual amounts of amortization expense may differ due to timing of regulatory approvals related to IPR&D assets, additional intangible assets acquired, impairment of intangible assets, and other events.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration